ABOS Stock Earnings: Acumen Pharmaceuticals Misses EPS for Q2 2024 ABOS stock results show that Acumen Pharmaceuticals missed analyst estimates for earnings per share the second quarter of 2024.
Trading SMID Biotech Stocks In A Volatile Market Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a broader market where technology rules.
ABOS Stock Earnings: Acumen Pharmaceuticals Beats EPS for Q1 2024 ABOS stock results show that Acumen Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024.
ABOS Stock Earnings: Acumen Pharmaceuticals Misses EPS for Q4 2023 ABOS stock results show that Acumen Pharmaceuticals missed analyst estimates for earnings per share the fourth quarter of 2023.
Earnings Scheduled For March 26, 2024 Companies Reporting Before The Bell • bluebird bio (
NASDAQ:BLUE ) is likely to report quarterly loss at $0.66 per share on revenue of $16.68 million.
Buy Alert: 3 Healthcare Stocks Sitting in the Sweet Spot Healthcare stocks to buy are not talked about as much right now, but are great stocks investors should consider adding.
3 Healthcare Stocks to Buy as the Sector Benefits from the Aging Boom These three aging stocks offer different thematic approaches to profit from the opportunities that exist in an aging population.
Are You A Trader Or Investor: Biotech Momentum Is Picking Up ETFs have not helped as portfolio fillers but they can identify trends. We should play this rally out of a biotech bear market.
Under the Microscope: 3 Biotech Stocks Pioneering Tomorrow’s Cures Unveil the resilience of biotech stocks as they outsmart market trends and champion the race for tomorrow's treatments.
3 Promising Biotech Stocks Flying Under the Radar Breakthroughs in healthcare are happening everyday, make sure you are keeping up to date on these under the radar biotech stocks.
Upcoming Phase 2 Data Expected For Longeveron's (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer's Sector – What To Look For Longeveron (
NASDAQ: LGVN ), a clinical-stage biopharma developing potential treatments for age-related and life-threatening diseases, is expecting data from its phase 2a trial for its Lomecel-B™ cellular drug in the next 3 to 4 months.
Earnings Scheduled For November 13, 2023 Companies Reporting Before The Bell • Sohu.com (
NASDAQ:SOHU ) is expected to report earnings for its third quarter. • Dixie Gr (
NASDAQ:DXYN ) is estimated to report earnings for its third quarter.
